Tarapeutics Science Inc.

Chinese Academy of Sciences

Precedo Pharmaceuticals Co., Ltd

Hefei Gracevo Bio-Medicine Co., Ltd

Shuang Qi

Cheng Chen

Jing Liu

Li Wang

Qingsong Liu

Beilei Wang

Wenchao Wang

Chen Hu

Aoli Wang

Wei Wang

Ziping Qi

Junjie Wang

Wenliang Wang

Hong Wu

Tao Ren

Xi Li

Fengming Zou

Kailin Yu

Yongfei Chen

Yun Wu

Ao Li Wang

Juan Liu

Zongru Jiang

Wen Chao Wang

Qing Song Liu

Qing Wang Liu

Wen Liang Wang

Bei Lei Wang

Feng Ming Zou

Zhenquan Hu

Qianmao Liang

Xuesong Liu

Jiang Yan Cao

Feiyang Liu

Xiaochuan Liu

Qiang Wang

Xi Xiang Li

Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.

MST1 kinase inhibitor and use thereof

Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFRα and/or PDGFRβ kinase activity.

Pyrazole derivatives and use thereof

Described herein is a kinase inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug of the compound. Further described herein is a pharmaceutical composition containing the kinase inhibitor compound, as well as methods of using the compound to inhibit cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 kinase activity in cells or a subject, and methods for preventing or treating disorders related to cKIT (especially mutant cKIT/T670I), FLT3 (comprising mutant FLT3-ITD), PDGFRα, PDGFRβ, and/or VEGFR2 activity in a subject.

Indazole kinase inhibitor and use thereof

The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases. 

Selective C-KIT kinase inhibitor

The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same. 

Irreversible bruton's tyrosine kinase inhibitor

Growing community of inventors

Anhui, China

Shuang Qi